RecruitingNot ApplicableNCT06184126

Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

Pilot Study to Investigate the Use of Virtual Reality Devices as an Adjunct to Usual Care for Patients With Sickle Cell Disease Experiencing Vaso-Occlusive Crises

Sponsor

University of Maryland, Baltimore

Enrollment

30 participants

Start Date

Nov 1, 2024

Study Type

INTERVENTIONAL

Conditions

Sickle Cell Disease Acute Pain Vaso-Occlusive Pain Episode in Sickle Cell Disease

Summary

This study aims to evaluate the use of virtual reality as an adjunct to standard care for patients with sickle cell disease experiencing vaso-occlusive crises.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Blindfolding and Noise Cancelling and a medical device called Virtual Reality Headset and Hand-Held Controllers for people with acute pain, sickle cell disease, and other related conditions. The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEVirtual Reality Headset and Hand-Held Controllers

Study Group-Virtual reality headset and hand-held controllers will be used as an adjuvant to pain management care.

OTHERBlindfolding and Noise Cancelling

Control group-Blindfold and noise cancelling headphones will be a placebo comparator group to the experimental interventions of virtual reality devices.

Locations(1)

University of Maryland Medical Systems

Baltimore, Maryland, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06184126

Related Trials

A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

NCT0643908232 locations

A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

NCT065466709 locations